Misty Dawn Shields
Misty Dawn Shields/X

Misty Dawn Shields: Tarlatamab-Induced Tumor Lysis Syndrome in Small Cell Carcinoma

Misty Dawn Shields, Assistant Professor at Indiana University School of Medicine, shared a post on X by Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, adding:

“Thank you Stephen Liu for sharing our recent case series highlighting a rare, but potentially serious AE (tumor lysis syndrome) with tarlatamab in SCLC in Clinical Lung Cancer.”

Quoting Stephen Lui’s post:

“Case series of tumor lysis syndrome with the bispecific T-cell engager tarlatamab in patients with small cell lung cancer Clinical Lung Cancer. I have not seen this myself, but for various reasons, tarlatamab in SCLC could be better with lower disease burden.”

Title: Tarlatamab-Induced Tumor Lysis Syndrome in Small Cell Carcinoma: Case Series

Authors: Brook M. Lobsiger, Ashley S. Huh-Brown, Jacob S. Edmisson, Brock O’Keefe, Jinesh Gheeya, Mark B. Botros, Asrar A. AlAhmadi, Misty D. Shields

Read further on Clinical Lung Cancer.

Tarlatamab-Induced Tumor

More posts featuring Misty Dawn Shields on OncoDaily.